JP6150813B2 - 増殖性疾患の治療方法 - Google Patents

増殖性疾患の治療方法 Download PDF

Info

Publication number
JP6150813B2
JP6150813B2 JP2014541283A JP2014541283A JP6150813B2 JP 6150813 B2 JP6150813 B2 JP 6150813B2 JP 2014541283 A JP2014541283 A JP 2014541283A JP 2014541283 A JP2014541283 A JP 2014541283A JP 6150813 B2 JP6150813 B2 JP 6150813B2
Authority
JP
Japan
Prior art keywords
braf
treatment
inhibitor
mutation
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014541283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533272A (ja
JP2014533272A5 (enExample
Inventor
スチュアート，ダリン
ダス サカー，メグナ
ダス サカー，メグナ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014533272A publication Critical patent/JP2014533272A/ja
Publication of JP2014533272A5 publication Critical patent/JP2014533272A5/ja
Application granted granted Critical
Publication of JP6150813B2 publication Critical patent/JP6150813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014541283A 2011-11-11 2012-11-09 増殖性疾患の治療方法 Expired - Fee Related JP6150813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
US61/558,619 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (3)

Publication Number Publication Date
JP2014533272A JP2014533272A (ja) 2014-12-11
JP2014533272A5 JP2014533272A5 (enExample) 2015-12-24
JP6150813B2 true JP6150813B2 (ja) 2017-06-21

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541283A Expired - Fee Related JP6150813B2 (ja) 2011-11-11 2012-11-09 増殖性疾患の治療方法

Country Status (10)

Country Link
US (1) US11007194B2 (enExample)
EP (1) EP2776037B1 (enExample)
JP (1) JP6150813B2 (enExample)
CN (2) CN103917236A (enExample)
AU (1) AU2012335663B2 (enExample)
BR (1) BR112014011223A8 (enExample)
CA (1) CA2855243C (enExample)
MX (1) MX354725B (enExample)
RU (1) RU2622015C2 (enExample)
WO (1) WO2013070996A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2882440B1 (en) * 2012-08-07 2019-02-27 Novartis AG Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX387795B (es) * 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
US11590133B2 (en) * 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN114929279A (zh) * 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
US12303509B2 (en) 2020-06-09 2025-05-20 Pfizer Inc. Compounds for the treatment of BRAF-associated diseases and disorders
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
HUP0001880A3 (en) 1997-05-22 2002-03-28 G D Searle & Co Chicago Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ES2295428T3 (es) 2001-10-25 2008-04-16 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2.
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
EP1682181A2 (en) 2003-09-23 2006-07-26 Novartis AG Combination of a vegf receptor inhibitor with a chemotherapeutic agent
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005068452A1 (en) 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
CN1960988B (zh) 2004-06-10 2012-01-25 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
CA2619035A1 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
EP2024353A2 (en) 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
EP2004165A2 (en) 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
US7501430B2 (en) 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
CN101815712A (zh) 2007-08-01 2010-08-25 辉瑞有限公司 吡唑化合物及其作为raf抑制剂的用途
CN101827584A (zh) 2007-10-19 2010-09-08 雅培股份有限两合公司 N-芳基脲基药物的固态分散体产品
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
EA201001456A1 (ru) 2008-03-21 2011-06-30 Новартис Аг Новые гетероциклические соединения и их применение
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009273197B2 (en) 2008-07-24 2014-01-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
US20110293750A1 (en) 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
ES2422263T3 (es) 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2011092088A1 (en) 2010-01-27 2011-08-04 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
HUE032100T2 (en) 2011-03-21 2017-08-28 Valcuria Ab A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use
US20140113919A1 (en) 2011-06-14 2014-04-24 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
DK2782557T3 (en) 2011-11-23 2018-12-10 Array Biopharma Inc PHARMACEUTICAL FORMULATIONS
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Also Published As

Publication number Publication date
HK1198920A1 (en) 2015-06-19
AU2012335663B2 (en) 2015-12-24
AU2012335663A1 (en) 2014-05-29
RU2014117707A (ru) 2015-12-20
CN103917236A (zh) 2014-07-09
CA2855243C (en) 2020-04-14
US20140275136A1 (en) 2014-09-18
RU2622015C2 (ru) 2017-06-08
EP2776037B1 (en) 2019-01-09
BR112014011223A8 (pt) 2023-01-31
MX354725B (es) 2018-03-16
BR112014011223A2 (pt) 2017-05-09
EP2776037A1 (en) 2014-09-17
CN108542906A (zh) 2018-09-18
CA2855243A1 (en) 2013-05-16
JP2014533272A (ja) 2014-12-11
US11007194B2 (en) 2021-05-18
WO2013070996A1 (en) 2013-05-16
MX2014005726A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
JP6150813B2 (ja) 増殖性疾患の治療方法
Li et al. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Zhao et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Tsimberidou Targeted therapy in cancer
Martinelli et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells
Sweetlove et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
Tanaka et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
Stein et al. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
Girotti et al. Deja Vu: EGF receptors drive resistance to BRAF inhibitors
Schmid et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
Naraev et al. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors
Imyanitov et al. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
Lara et al. Targeting MEK in non-small cell lung cancer
Ding et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2
Ye et al. Integration of AKT and ERK signaling pathways in cancer: biological and therapeutic implications
HK1198920B (en) Method of treating a proliferative disease
McDermott et al. Allosteric MEK1/2 inhibitors for the treatment of cancer: an overview
Kursunluoglu et al. Cancer Therapies
Fava et al. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant
Moschopoulou et al. Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
Khan et al. An update on BRAF inhibitors and other new molecular targets for the treatment of malignant melanoma of the skin
Ahn Molecular targeted therapy in lung cancer
Wang et al. Conformation-specific inhibitors of Raf kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170523

R150 Certificate of patent or registration of utility model

Ref document number: 6150813

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees